Posted by Michael Wonder on 28 May 2021
NICE green lights Tremfya to treat active psoriatic arthritis
28 May 2021 - Janssen’s IL-23 inhibitor Tremfya has been accepted for NHS use by the UK’s NICE for the treatment of active psoriatic arthritis.
Tremfya (guselkumab) is a fully human monoclonal antibody designed to selectively bind to and inhibit the IL-23 receptor – an key driver of progression in inflammatory diseases such as psoriatic arthritis.
